Literature DB >> 29273868

Involvement of TLR3-Dependent PGES Expression in Immunosuppression by Human Bone Marrow Mesenchymal Stem Cells.

Dae Seong Kim1,2, Whi Hyeong Lee3, Myoung Woo Lee4,5, Hyun Jin Park1,2, In Keun Jang6, Ji Won Lee1, Ki Woong Sung1, Hong Hoe Koo1,2,7, Keon Hee Yoo8,9,10.   

Abstract

Human mesenchymal stem cells (MSCs) are known for their prostaglandin E2 (PGE2)-mediated immunosuppressive function but the precise molecular mechanisms underlying PGE2 biosynthesis during inflammation have not been completely elucidated. In this study, we have investigated the involvement of PGE2 pathway members in PGE2 production by bone marrow (BM)-MSCs in response to inflammatory stimuli, and their role in immunosuppression mediated by BM-MSCs. We found that IFN-γ and TNF-α increased cyclooxygenase (COX)-2 expression but not that of prostaglandin E synthase (PGES), or PGE2 production. On the other hand, the toll like receptor 3 (TLR3) stimulant poly(I:C) increased expression of both COX-2 and PGES, resulting in a significant increase in PGE2 levels. This effect was reversed upon COX-2 inhibition with indomethacin or PGES downregulation by siRNA. Reduced PGE2 levels decreased MSC's capacity to inhibit hPBMC proliferation. In addition, administration of MSCs with inhibited PGES expression into mice with graft-versus-host disease (GVHD) did not reduce mortality. In summary, the present study reveals that upregulation of PGES via TLR3 is critical for BM-MSCs-mediated immunosuppression by PGE2 secretion via the COX-2/PGE2 pathway. These results provide a basis for understanding the molecular mechanisms underlying the PGE2-mediated immunosuppressive properties of MSCs.

Entities:  

Keywords:  Cyclooxygenase 2; Immunosuppression; Mesenchymal stem cell; Prostaglandin E synthase; Prostaglandin E2

Mesh:

Substances:

Year:  2018        PMID: 29273868     DOI: 10.1007/s12015-017-9793-6

Source DB:  PubMed          Journal:  Stem Cell Rev Rep        ISSN: 2629-3277            Impact factor:   5.739


  31 in total

1.  Soluble molecules are key in maintaining the immunomodulatory activity of murine mesenchymal stromal cells.

Authors:  Hua Liu; Kai Lu; Paul Anthony MacAry; Kok Loon Wong; Alexis Heng; Tong Cao; David Michael Kemeny
Journal:  J Cell Sci       Date:  2012-01-16       Impact factor: 5.285

2.  Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources.

Authors:  Mehdi Najar; Gordana Raicevic; Hicham Id Boufker; Hussein Fayyad Kazan; Cécile De Bruyn; Nathalie Meuleman; Dominique Bron; Michel Toungouz; Laurence Lagneaux
Journal:  Cell Immunol       Date:  2010-06-18       Impact factor: 4.868

3.  Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells.

Authors:  Kazuya Sato; Katsutoshi Ozaki; Iekuni Oh; Akiko Meguro; Keiko Hatanaka; Tadashi Nagai; Kazuo Muroi; Keiya Ozawa
Journal:  Blood       Date:  2006-09-19       Impact factor: 22.113

4.  Activated T-cells and pro-inflammatory cytokines differentially regulate prostaglandin E2 secretion by mesenchymal stem cells.

Authors:  Beáta Hegyi; Gyöngyi Kudlik; Eva Monostori; Ferenc Uher
Journal:  Biochem Biophys Res Commun       Date:  2012-02-07       Impact factor: 3.575

5.  Human mesenchymal stem cells modulate allogeneic immune cell responses.

Authors:  Sudeepta Aggarwal; Mark F Pittenger
Journal:  Blood       Date:  2004-10-19       Impact factor: 22.113

6.  Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation.

Authors:  Roland Meisel; Andree Zibert; Maurice Laryea; Ulrich Göbel; Walter Däubener; Dagmar Dilloo
Journal:  Blood       Date:  2004-03-04       Impact factor: 22.113

7.  MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2.

Authors:  Grazia Maria Spaggiari; Heba Abdelrazik; Flavio Becchetti; Lorenzo Moretta
Journal:  Blood       Date:  2009-04-27       Impact factor: 22.113

Review 8.  Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases.

Authors:  Jean Y Park; Michael H Pillinger; Steven B Abramson
Journal:  Clin Immunol       Date:  2006-03-15       Impact factor: 3.969

9.  Suppression of IL-10 production by activated B cells via a cell contact-dependent cyclooxygenase-2 pathway upregulated in IFN-γ-treated mesenchymal stem cells.

Authors:  Barbora Hermankova; Alena Zajicova; Eliska Javorkova; Milada Chudickova; Peter Trosan; Michaela Hajkova; Magdalena Krulova; Vladimir Holan
Journal:  Immunobiology       Date:  2015-09-12       Impact factor: 3.144

10.  In vitro and in vivo immunosuppressive characteristics of hepatocyte growth factor-modified murine mesenchymal stem cells.

Authors:  Li Bian; Zi-Kuan Guo; Heng-Xiang Wang; Jin-Song Wang; Hua Wang; Qing-Fang Li; Yue-Feng Yang; Feng-Jun Xiao; Cu-Tse Wu; Li-Sheng Wang
Journal:  In Vivo       Date:  2009 Jan-Feb       Impact factor: 2.155

View more
  8 in total

Review 1.  Current understanding of the immunosuppressive properties of mesenchymal stromal cells.

Authors:  Ligia Lins de Castro; Miquéias Lopes-Pacheco; Daniel Jay Weiss; Fernanda Ferreira Cruz; Patricia Rieken Macêdo Rocco
Journal:  J Mol Med (Berl)       Date:  2019-03-22       Impact factor: 4.599

2.  Immunopathology in schistosomiasis is regulated by TLR2,4- and IFN-γ-activated MSC through modulating Th1/Th2 responses.

Authors:  Chao Liu; Yi-Shu Zhang; Fang Chen; Xiao-Ying Wu; Bei-Bei Zhang; Zhong-Dao Wu; Jun-Xia Lei
Journal:  Stem Cell Res Ther       Date:  2020-06-05       Impact factor: 6.832

Review 3.  Key Metabolic Pathways in MSC-Mediated Immunomodulation: Implications for the Prophylaxis and Treatment of Graft Versus Host Disease.

Authors:  Andre J Burnham; Elisabetta Manuela Foppiani; Edwin M Horwitz
Journal:  Front Immunol       Date:  2020-12-07       Impact factor: 7.561

Review 4.  Mesenchymal Stem Cell-Based Therapy for Rheumatoid Arthritis.

Authors:  Madina Sarsenova; Assel Issabekova; Saule Abisheva; Kristina Rutskaya-Moroshan; Vyacheslav Ogay; Arman Saparov
Journal:  Int J Mol Sci       Date:  2021-10-27       Impact factor: 5.923

Review 5.  Advances in mesenchymal stromal cell therapy for acute lung injury/acute respiratory distress syndrome.

Authors:  Chang Liu; Kun Xiao; Lixin Xie
Journal:  Front Cell Dev Biol       Date:  2022-08-10

Review 6.  Recent advances to enhance the immunomodulatory potential of mesenchymal stem cells.

Authors:  Madina Sarsenova; Yevgeniy Kim; Kamila Raziyeva; Bexultan Kazybay; Vyacheslav Ogay; Arman Saparov
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

Review 7.  Functional enhancement strategies for immunomodulation of mesenchymal stem cells and their therapeutic application.

Authors:  Byung-Chul Lee; Kyung-Sun Kang
Journal:  Stem Cell Res Ther       Date:  2020-09-14       Impact factor: 6.832

Review 8.  Essential Fatty Acids and Their Metabolites in the Pathobiology of Inflammation and Its Resolution.

Authors:  Undurti N Das
Journal:  Biomolecules       Date:  2021-12-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.